Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ranibizumab

Ranibizumab Anti-FAB fragment of VEGF Macular degeneration... [Pg.603]

Ranibizumab (Lucentis) Humanized antibody fragment, IgG-) VEGF-A Inhibition of ligand binding AMD... [Pg.1255]

VEGF inhibitors have demonstrated a marked clinical benefit also in wet AMD. Blockade of all VEGF-A isoforms and bioactive fragmemts with ranibizumab not only slowed down vision loss, but unexpectedly appears to have the potential to enable many AMD patients to obtain a meaningful and sustained gain of vision. Further research is needed to determine whether the vision gain conferred by ranibizumab extends beyond 24 months and whether additional intraocular neovascular syndromes may benefit from this treatment. [Pg.1272]

Ferrara N, Damico L, Shams N, et al (2006) Developmemt of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 859-870... [Pg.1272]

Ranibizumab is produced in E. coli expression system in a nutrient medium containing the tetracycline antibiotic. It has a molecular weight of 48 kDa. [Pg.121]

Lucentis contains ranibizumab and is available for intravitreal injection. It is a vascular endothelial growth factor inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration. Unlike verteporfin, which is used in photodynamic treatment of age-related macular degeneration, ranibizumab does not require activation by local irradiation using non-thermal red light. [Pg.154]

Neovascular macular degeneration Ranibizumab (labeled), bevacizumab (unlabeled) Fair... [Pg.1190]

Lucentis Ranibizumab Genentech/Novartis Marketed product Exudative AMD Intravitreal injection... [Pg.35]

See other pages where Ranibizumab is mentioned: [Pg.604]    [Pg.1010]    [Pg.1256]    [Pg.1271]    [Pg.596]    [Pg.601]    [Pg.509]    [Pg.534]    [Pg.534]    [Pg.535]    [Pg.597]    [Pg.603]    [Pg.121]    [Pg.348]    [Pg.272]    [Pg.272]    [Pg.461]    [Pg.1197]    [Pg.1207]    [Pg.1280]    [Pg.272]    [Pg.272]    [Pg.947]    [Pg.604]    [Pg.1010]    [Pg.1256]    [Pg.1271]    [Pg.305]    [Pg.306]    [Pg.306]    [Pg.306]    [Pg.307]   
See also in sourсe #XX -- [ Pg.509 , Pg.534 ]

See also in sourсe #XX -- [ Pg.154 , Pg.348 ]

See also in sourсe #XX -- [ Pg.272 ]

See also in sourсe #XX -- [ Pg.447 ]

See also in sourсe #XX -- [ Pg.272 ]

See also in sourсe #XX -- [ Pg.306 ]

See also in sourсe #XX -- [ Pg.73 , Pg.74 , Pg.258 ]

See also in sourсe #XX -- [ Pg.272 ]

See also in sourсe #XX -- [ Pg.258 ]

See also in sourсe #XX -- [ Pg.351 , Pg.354 , Pg.355 ]

See also in sourсe #XX -- [ Pg.580 ]



SEARCH



Ranibizumab degeneration

Ranibizumab detachment

Ranibizumab intravitreal injection

Ranibizumab macular edema

Ranibizumab retinal pigment epithelial

© 2024 chempedia.info